Table 2.
Serum Inaba Vibriocidal Antibody Responses to Vaccination, by Day Relative to Vaccination
| Blinded Study Product |
Baseline | Day 7 | Day 10 | Day 28a | Day 90a | Day 180a |
|---|---|---|---|---|---|---|
| No. With Seroconversion (%) | ||||||
| Vaccine | n = 94 | 75 (79.8) | 84 (89.4) | 85 (90.4) | 85 (90.4) | 85 (90.4) |
| Placebo | n = 102 | 2 (2.0) | 2 (2.0) | 2 (2.0) | 2 (2.0) | 2 (2.0) |
| Geometric mean titer (95% CI) | ||||||
| Vaccine | 46.0 (36.5–58.1) | 830.8 (554.5–1245) | 4313 (2873–6476) | 1394 (866.4–2242) | 270.5 (158.3–462.2) | 155.4 (82.2–293.9) |
| Placebo | 63.1 (47.5–83.7) | 65.4 (48.3–88.6) | 64.8 (47.8–87.9) | 50.6 (35.9–71.2) | 48.3 (29.8–78.5) | 62.2 (35.9–107.7) |
Abbreviation: CI, confidence interval.
a Individuals challenged on day 10 were not included in the calculation of 28-, 90-, and 180-day postvaccination immune responses; individuals challenged at 3 months were not included in the calculation of 180-day postvaccination immune responses.